tiprankstipranks
TipRanksTop Financial ExpertsInsidersJohn Smither

John Smither Insider Profile

4 Followers
John Smither, Director at NewAmsterdam Pharma Company, holds 8.76K shares in NewAmsterdam Pharma Company (Ticker: NAMS), holds 28.00K shares in MBX Biosciences, Inc. (Ticker: MBX), holds 91.40K shares in Genelux Corp. (Ticker: GNLX). Most recently, John Smither Sold ― shares of NewAmsterdam Pharma Company on Sep 09, 2026 for an estimated value of $40.51K.
See the Hottest Stocks Based on Insider Trading >
tipranks
John Smither

John Smither
NewAmsterdam Pharma Company (NAMS)
Director

Ranked #18,192 out of 109,030 Corporate Insiders

Profitable Transactions

60%
6 out of 10 Profitable Transactions

Average Return

+10.30%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
How are Insiders Ranked?

Insider Holdings

$6M
63.69%
28.85%
3.97%
3.49%
<0.01% Others
A breakdown of John Smither's holdings
See the Top Stocks by Insiders

Insider Roles

Arcutis Biotherapeutics
(ARQT)
CFO
MBX Biosciences, Inc.
(MBX)
Chief Financial Officer
Genelux Corp.
(GNLX)
Director
NewAmsterdam Pharma Company
(NAMS)
Director
+2 other positions
Roles that John Smither holds in companies
See the Top Corporate Insiders

Most Profitable Insider Trade

Stock:
Genelux Corp.
(GNLX)
Rating:Informative Sell
Date:Sep 14, 2023 - Sep 14, 2024
Return:+88.90%
The most profitable trade made by John Smither
See the Latest Stocks Traded by Insiders

John Smither's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
NAMS
NewAmsterdam Pharma Company
Sep 09, 2026
Director
Informative Sell
40.51K
$199.73K
MBX
MBX Biosciences, Inc.
Aug 04, 2026
Chief Financial Officer
Uninformative Buy
―
$1.65M
KYTH
Kythera
Oct 02, 2015
―
Uninformative Sell
―
$0.00
SNNAQ
Sienna Biopharmaceuticals
Jan 03, 2019
CFO
Uninformative Buy
―
―
PRNB
Principia Biopharma
―
―
―
―
ARQT
Arcutis Biotherapeutics
Feb 15, 2024
CFO
Uninformative Buy
―
$3.65M
EFTR
eFFECTOR Therapeutics
Aug 27, 2021
Director
Uninformative Buy
―
$482.84
AMTI
Applied Molecular Transport
―
―
―
―
GNLX
Genelux Corp.
Jul 02, 2026
Director
Informative Sell
34.80K
$227.59K
AKAOQ
Achaogen
―
―
―
$0.00
List of latest transactions for each holding click on a transaction to see John Smither's performance on stock
See All Insider Trading from Today

You May Also Like

Meet our Smart Portfolio. See what top analysts say about your stocks.Get a breakdown of the different strategies based on detected insider trading activity.Find the best performing Analyst in each sector. Follow them so you never miss a recommendation.

John Smither insider profile FAQ

What is the percentage of profitable transactions made by John Smither?
The percentage of profitable transactions made by John Smither is 60%.
    What is the average return per transaction made by John Smither?
    The average return per transaction made by John Smither is 10.30%.
      What stocks does John Smither hold?
      John Smither holds: NAMS, MBX, KYTH, SNNAQ, PRNB, ARQT, EFTR, AMTI, GNLX, AKAOQ stocks.
        What was John Smither’s latest transaction?
        John Smither latest transaction was an Informative Sell of $40.51K.
          What was John Smither's most profitable transaction?
          John Smither’s most profitable transaction was an Informative Sell of GNLX stock on September 14, 2023. The return on the trade was 88.90%.
            What is John Smither's role in NewAmsterdam Pharma Company?
            John Smither's role in NewAmsterdam Pharma Company is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.